Anti-SF-25 monoclonal antibody

Drug Profile

Anti-SF-25 monoclonal antibody

Alternative Names: Monoclonal antibody SF-25; SF-25

Latest Information Update: 25 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard University; Massachusetts General Hospital
  • Developer Panacea Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 26 Sep 2006 This programme is still in active development for cancer
  • 17 Sep 2003 SF-25 has been licensed to Panacea worldwide
  • 10 Apr 1995 Preclinical development for Cancer in USA (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top